The "cancer-targeting" antibodies that are currently in Phase I/II clinical trials include CD98
antibody, killer-cell immunoglobulin-like receptor (KIR) antibody, programed cell death protein 1 (PD1) antibody, Stage II-specific human thymocyte differentiation antigen (JL1) antibody, cytotoxic T-lymphocyte associated protein 4 (CTLA4) antibody, and CXCR4 antibody.
Overexpression of MARCH1 in HeLa cells causes CD98 to be trafficked via EEA1 positive compartments and late endosomes rather than clathrin independent endocytosis .
2, TfR, CD166, CD44, CD88, and CD98, indicating that it plays a significant role in immune suppression [6, 15, 30, 31, 37, 46, 95, 96].
CD44 and CD98 are normally trafficked via a clathrin independent endocytosis pathway, whereby rather than being sorted into early endosomal antigen 1 (EEA1) positive endosome, they enter the tubular recycling endosomes directly.
Tetraspan antigens and CD98 presented rather unique staining pattern in OA synovium suggesting special roles for each antigen on the synovial lining layer (SLL).
An intense reaction on the SLL and vascular endothelium was noted for CD98 in both normal and OA groups.
CD98 presented an intense reaction on the SLL and vascular endothelium in both groups; its immunoreactivity was prominent at the outermost lining type A macrophagelike cell layer and stromal macrophages in the OA group.